Experimental evidence shows that the administration of the endocannabinoid anandamide (AEA) can antagonize epileptic discharges in the hippocampal tissue of animal models. In this report, we measured the levels of AEA and the levels of the other endocannabinoid 2-arachidonoylglycerol (2-AG) in the cerebrospinal fluid (CSF) of drug-naïve patients with partial epilepsy.We found a significant reduction of AEA (down to ∼20%) in the CSF of epileptic patients compared with healthy controls (P <0.01). Instead, 2-AG levels were not affected (P = 0.48) and no correlation was found between AEA and either disease duration or patient age.Our results support the hypothesis of a different involvement of endocannabinoids in epilepsy.
|Translated title of the contribution||The endocannabinoid system is disregulated in untreated partial epilepsy: CSF findings|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 2008|
ASJC Scopus subject areas
- Clinical Neurology